Previous Page  39 / 49 Next Page
Show Menu
Previous Page 39 / 49 Next Page
Page Background

Partnership with adult oncology

During the last 50 years, paediatric

oncology has developed in relative isolation.

Improving the cooperation of all paediatric

haematologists and oncologists was

the crucial objective so that an effective

European clinical research programme could

be set up and address the very specific

needs of children with cancers without

reference to adult cancer services.

It is now recognised that adult and

paediatric oncology have a lot to share

and learn from each other, and that

collaboration is beneficial in order to

address common goals and challenges:


Care and research for rare cancers,

in terms of innovative methodology to

evaluate new treatments and in terms

of health care organisation models to

provide access to expertise for patients

suffering from rare and extremely rare



Care and research for TYA (see above);


Access to essential medicines, since most

anti-cancer drugs are used to treat

both adult and paediatric cancers, even

though there are differences in the



European initiatives on care and research


SIOPE and ESMO (the European Society

of Medical Oncology) have decided to

develop a joint initiative to address those

topics, and established a Memorandum of

Understanding to help this collaboration.

Partnership with paediatric

haematology-oncology in other


SIOPE is part of the global paediatric

oncology agenda run by the International

Society of Paediatric Oncology (SIOP).

Several European-centred study groups

have an international scope, and bring

together global investigators to participate

in a common clinical trials portfolio.

The IBFM-study group is international, and

patients from countries outside Europe

participate to its leukaemia trials and

translational research projects.

More than a hundred institutions from

Europe, Asia, Central and South America,

Australia and New Zealand collaborate in

SIOPEL, the SIOPE-liver study group. Early

drug trial groups such as ITCC in Europe,

the Pediatric Oncology Experimental

Therapeutics Investigator’s Consortium

(POETIC) and Therapeutic Advances in

Childhood Leukemia and Lymphoma (TACL)

in North America, the Canadian C17 network,

the Australia Children’s Cancer Trials group

and the Children Oncology Group (COG)

phase I consortium are working together

to speed up the development of new

anticancer agents.



Credit Hellenic Society of Paediatric Haematology-Oncology

(HeSPHO), Greece